G1 Therapeutics turned research from the University of North Carolina at Chapel Hill into novel cancer drug Cosela, which is approved in the U.S. and China. Pharmacosmos says its G1 acquisition will enable Cosela to reach more lung cancer patients around the world.
Science 37 rode the trends of Covid-19 technologies and SPAC mergers to a more than $1 billion valuation. But revenue for the decentralized clinical trials software firm stopped growing, and it’s now going private valued at just $38 million.
Healthcare is drowning in chaos—from scattered data to burnout-inducing tasks. Discover how smarter workflows and real-time insights can rescue care teams and transform patient outcomes.
Gene therapy biotech Kriya Therapeutics has acquired Tramontane Therapeutics, a startup focused on metabolic diseases. Tramontane brings a gene therapy that’s a potential one-time treatment for the fatty liver disease NASH.
G1 Therapeutics said its drug met the main goal of a Phase 3 study in colorectal cancer, but the preliminary results also show measures of survival are better in the placebo arm. The company is stopping the colorectal cancer study.
Lusaris Therapeutics launched with $60 million for clinical development of a psychedelic depression drug it claims will be easier to dose and fast-acting. The company was formed and incubated by RA Capital Management, which led the startup’s Series A round of financing.
A Fennec Pharmaceuticals drug that prevents hearing loss in children receiving cancer treatment is now approved. The regulatory decision comes more than two years later than expected, but the company now claims its drug, Pedmark, is the first and only FDA-approved therapy for reducing the risk of chemotherapy-induced hearing loss in pediatric cancer patients.
Get your IV treatment from wherever you are. These top companies provide mobile IV therapy administered by experienced nurses in NYC and beyond.
Creyon Bio is the latest company to launch with artificial intelligence technology for drug R&D. The startup claims its technology can provide sufficient safety and toxicity data to enable a therapy to bypass the animal research currently needed before clinical trials.
The deal, offering $2 billion up front and $2 billion in future milestone payments, includes a gene therapy manufacturing facility and a pipeline that includes treatments for Parkinson's and congestive heart failure.
The agency granted an emergency use authorization to the company for its test, which is meant to detect antibodies against SARS-CoV-2 in the blood. However, antibody testing has both advantages and disadvantages relative to the more common PCR assays.
The use of coupons and manufacturer buydowns is increasing as a way to offset what would otherwise be increasing costs borne by the patients, according to Murray Aitken, senior vice president and executive director of the IQVIA Institute for Human Data Science,
Who accredits health plans for mental health parity compliance? Learn about the only organization that offers this program to ensure your members get equitable care.
In June, Quintiles launched a continuous glucose monitoring service, combining consumer wearable devices and medical device CGM to record glucose readings throughout the day.
CEO of surgical robotics company TransEnterix talks of interactions with FDA that rejected its 510(k) application but refuses to divulge the reason that led to the agency's negative decision frustrating analysts and investors.
New investor Hatteras Venture Partners and existing investor Excelerate Health Ventures co-led the round.
It also projects $5 million in revenue this year.
Forecast Health recently raised $1.45 million from a super angel to grow its national sales team.